These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 22429586)

  • 21. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
    Papp KA; Langley RG; Sigurgeirsson B; Abe M; Baker DR; Konno P; Haemmerle S; Thurston HJ; Papavassilis C; Richards HB
    Br J Dermatol; 2013 Feb; 168(2):412-21. PubMed ID: 23106107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).
    Barker J; Hoffmann M; Wozel G; Ortonne JP; Zheng H; van Hoogstraten H; Reich K
    Br J Dermatol; 2011 Nov; 165(5):1109-17. PubMed ID: 21910713
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An observational, prospective study of monthly adalimumab therapy for disease maintenance in psoriasis patients: a possible new therapeutic option for good responders to the initial induction treatment.
    Taniguchi T; Noda S; Takahashi N; Yoshimura H; Mizuno K; Adachi M
    J Eur Acad Dermatol Venereol; 2013 Nov; 27(11):1444-7. PubMed ID: 22702802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adalimumab treatment optimization for psoriasis: Results of a long-term phase 2/3 Japanese study.
    Asahina A; Ohtsuki M; Etoh T; Gu Y; Okun MM; Teixeira HD; Yamaguchi Y; Nakagawa H
    J Dermatol; 2015 Nov; 42(11):1042-52. PubMed ID: 26118825
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial.
    Kimball AB; Kerdel F; Adams D; Mrowietz U; Gelfand JM; Gniadecki R; Prens EP; Schlessinger J; Zouboulis CC; van der Zee HH; Rosenfeld M; Mulani P; Gu Y; Paulson S; Okun M; Jemec GB
    Ann Intern Med; 2012 Dec; 157(12):846-55. PubMed ID: 23247938
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial.
    Leonardi C; Langley RG; Papp K; Tyring SK; Wasel N; Vender R; Unnebrink K; Gupta SR; Valdecantos WC; Bagel J
    Arch Dermatol; 2011 Apr; 147(4):429-36. PubMed ID: 21173304
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An assessment of adalimumab efficacy in three Phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals.
    Mrowietz U; Kragballe K; Reich K; Griffiths CE; Gu Y; Wang Y; Rozzo SJ
    Br J Dermatol; 2013 Feb; 168(2):374-80. PubMed ID: 22880843
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.
    Menter A; Tyring SK; Gordon K; Kimball AB; Leonardi CL; Langley RG; Strober BE; Kaul M; Gu Y; Okun M; Papp K
    J Am Acad Dermatol; 2008 Jan; 58(1):106-15. PubMed ID: 17936411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
    Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM
    Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE.
    Ortonne JP; Chimenti S; Reich K; Gniadecki R; Sprøgel P; Unnebrink K; Kupper H; Goldblum O; Thaçi D
    J Eur Acad Dermatol Venereol; 2011 Sep; 25(9):1012-20. PubMed ID: 21214631
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intermittent etanercept therapy in pediatric patients with psoriasis.
    Siegfried EC; Eichenfield LF; Paller AS; Pariser D; Creamer K; Kricorian G
    J Am Acad Dermatol; 2010 Nov; 63(5):769-74. PubMed ID: 20833444
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI; Hooft L
    Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy.
    Genovese MC; Mease PJ; Thomson GT; Kivitz AJ; Perdok RJ; Weinberg MA; Medich J; Sasso EH;
    J Rheumatol; 2007 May; 34(5):1040-50. PubMed ID: 17444593
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis.
    Takahashi H; Tsuji H; Ishida-Yamamoto A; Iizuka H
    J Dermatol; 2013 Jan; 40(1):39-42. PubMed ID: 23039179
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment.
    Papp K; Leonardi C; Menter A; Thompson EH; Milmont CE; Kricorian G; Nirula A; Klekotka P
    J Am Acad Dermatol; 2014 Dec; 71(6):1183-1190.e3. PubMed ID: 25313095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adalimumab plus narrowband ultraviolet B light phototherapy for the treatment of moderate to severe psoriasis.
    Bagel J
    J Drugs Dermatol; 2011 Apr; 10(4):366-71. PubMed ID: 21455546
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial.
    Thaçi D; Vender R; de Rie MA; Conrad C; Pariser DM; Strober B; Vanvoorden V; Wang M; Madden C; de Cuyper D; Kimball AB
    Br J Dermatol; 2023 Jan; 188(1):22-31. PubMed ID: 36689515
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study.
    Gordon KB; Langley RG; Leonardi C; Toth D; Menter MA; Kang S; Heffernan M; Miller B; Hamlin R; Lim L; Zhong J; Hoffman R; Okun MM
    J Am Acad Dermatol; 2006 Oct; 55(4):598-606. PubMed ID: 17010738
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A multicenter open-label experience on the response of psoriasis to Adalimumab and effect of dose escalation in non-responders: the Aphrodite project.
    Vena GA; Galluccio A; De Simone C; Mastrandrea V; Buquicchio R; La Greca S; Dattola S; Puglisi Guerra A; Donato L; Cantoresi F; De Pità O; Pezza M; D Agostino M; Vernaci R; Miracapillo A; Valenti G; Cassano N
    Int J Immunopathol Pharmacol; 2009; 22(1):227-33. PubMed ID: 19309570
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship between methotrexate dosing and clinical response in patients with moderate to severe psoriasis: subanalysis of the CHAMPION study.
    Saurat JH; Langley RG; Reich K; Unnebrink K; Sasso EH; Kampman W
    Br J Dermatol; 2011 Aug; 165(2):399-406. PubMed ID: 21564071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.